Physician profile
Carrie Grounds
NPI 1326044371
$3,049.65
in general payments reported to CMS, 2019-2025
31 companies · $666 in 2025
The $666 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $126 · 2022: $634 · 2023: $647 · 2024: $628 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $368.11 | 2019-2023 | |
| Biogen, INC. | $361.01 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $285.66 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $247.84 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $217.82 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $209.02 | 2022-2024 | Paragard T 380a |
| Pfizer INC. | $198.29 | 2019-2024 | |
| Daiichi Sankyo INC. | $145.93 | 2019-2023 | Injectafer |
| Organon LLC | $100.14 | 2024-2025 | Nexplanon |
| Medtronic, INC. | $97.81 | 2022-2024 | Ligasure |
| Channel Medsystems, INC. | $92.66 | 2023 | |
| Therapeuticsmd, INC. | $79.51 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.74 | 2019-2025 | |
| Millicent US INC | $70.49 | 2025 | Intrarosa, Femring, Femlyv |
| Myriad Women'S Health, INC. | $68.11 | 2023 | Myrisk |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $66.14 | 2019-2024 | Thinprep 2000 Processor, Aptima, Third Wave |
| Dexcom, INC. | $50.47 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $46.08 | 2025 | |
| Myovant Sciences INC. | $45.56 | 2022 | |
| Merck Sharp & Dohme LLC | $41.08 | 2019-2025 | Gardasil 9 |
| Agile Therapeutics, INC. | $29.94 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.35 | 2022 | |
| Mission Pharmacal Company | $20.08 | 2020 | |
| Pharmacosmos Therapeutics INC. | $19.16 | 2024 | Monoferric |
| Exeltis, USA INC. | $16.04 | 2024 | Slynd |
| Karl Storz Endoscopy-America | $14.63 | 2019 | |
| Allergan, INC. | $13.64 | 2019 | |
| Minerva Surgical, INC | $13.62 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.27 | 2019 | |
| Evofem Biosciences, INC. | $12.78 | 2022 | |
| Covidien Lp | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Grounds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.